

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

AMENDMENT NO. 1 TO  
FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES  
PURSUANT TO SECTION 12(b) OR (g) OF THE  
SECURITIES EXCHANGE ACT OF 1934

CYPROS PHARMACEUTICAL CORPORATION  
(Exact name of registrant as specified in its charter)

California 33-0476164  
(State of incorporation or (I.R.S. Employer  
organization) Identification No.)

2714 Loker Avenue West  
Carlsbad, California 92008  
(Address of principal executive (Zip Code)  
offices)

Securities to be registered  
pursuant to Section  
12(b) of the Act:

Title of each class to be so registered	Names of each exchange on which each class is to be registered
--	--

Common Stock, no par value	American Stock Exchange, Inc.
----------------------------	-------------------------------

If this Form relates to the registration of a class of debt  
securities and is effective upon filing pursuant to General  
Instruction A.(c)(1), please check the following box [ ]

If this Form related to the registration of a class of debt  
securities and is to become effective simultaneously with the  
effectiveness of a concurrent registration statement under the  
Securities Act of 1933 pursuant to General Instruction A.(c)(2),  
please check the following box [ ]

Securities to be registered pursuant to Section 12(g) of the Act:

(Title of class)

#### INFORMATION REQUIRED IN REGISTRATION STATEMENT

Item 1. Description of Registrant's Securities to be Registered.

A description of the Common Stock to be registered hereunder is  
contained in the section entitled "Description of Securities" on  
page 40 of the Prospectus included in the Registrant's Form S-1  
Registration Statement (No. 33-51682) and is incorporated herein  
by reference.

Item 2. Exhibits

None.

#### SIGNATURES

Pursuant to the requirements of Section 12 of the Securities  
Exchange Act of 1934, the registrant has duly caused this  
registration statement to be signed on its behalf by the  
undersigned, thereto duly authorized.

(Registrant): CYPROS PHARMACEUTICAL CORPORATION

Date: January 14, 1998

By: /s/David W Nassif

- - - - -  
David W. Nassif

Senior Vice President and Chief Financial Officer